Full Press Release Details
CAMBRIDGE, Mass., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Medical Officer John Leonard, M.D., will participate in a panel discussion and present a company overview at the Jefferies Gene Editing/Therapy Summit on Tuesday, October 11, 2016.
Details of the presentation are as follows:
Jefferies Gene Editing/Therapy Summit
Date: Tuesday, October 11, 2016
Location: New York, New York
Times: Panel discussion at 10:00 am ET with company presentation to follow at 2:00 pm ET.
About Intellia Therapeutics
Contact Data
Jennifer Mound Smoter
Chief External Affairs & Communications Officer
Contact
With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.